EyePoint Reports Q4 Revenue of $620K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy EYPT?
Reports Q4 revenue $620k, consensus $1.01M. "Following a year of exceptional execution across our pivotal DURAVYU programs, EyePoint enters 2026 from a position of strength as we prepare to deliver on key Phase 3 milestones and showcase the potential of DURAVYU's best-in-class safety and efficacy profile," said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. "We expect to report Phase 3 topline data in wet AMD beginning in mid-2026, and we are confident that our de-risked approach and non-inferiority pathway position us to potentially obtain a broad and favorable label. DURAVYU is the only TKI in development for the treatment of DME and, with the recent first patient dosing in our COMO and CAPRI Phase 3 trials, we now have active pivotal programs in the largest multi-billion-dollar retina markets. Our clinical timeline positions DURAVYU to be first to market among current investigational sustained delivery programs in these large and growing indications."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.670
Low
20.00
Averages
31.50
High
43.00
Current: 15.670
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific company names and rating changes are not detailed in the report, such adjustments typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention.
- Market Reaction Expectations: The adjustments made by analysts may trigger market volatility, especially when investor sentiment towards certain stocks is sensitive, potentially leading to increased trading volumes in the short term.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their strategies regarding buying or holding these stocks, thereby affecting overall market liquidity.
See More
EyePoint, Inc. Q4 2025 Earnings Call Insights
- Significant Clinical Progress: EyePoint initiated pivotal Phase III trials for DME in Q4 2025, marking a crucial advancement for DURAVYU, with top line data for wet AMD expected in mid-2026, thereby laying a strong foundation for future market potential.
- Strong Financial Position: By the end of 2025, EyePoint reported $306 million in cash and investments, despite a significant drop in Q4 net revenue to $0.6 million from $11.6 million in Q4 2024, primarily due to the recognition of deferred revenue from the YUTIQ licensing agreement.
- Rising Operating Expenses: Operating expenses for Q4 2025 reached $71 million, up from $57 million in the prior year, reflecting increased trial activities for DURAVYU, although the company expects its cash runway to extend into Q4 2027.
- Positive Safety Data: Among 191 patients, DURAVYU exhibited a low adverse event rate, with cataract incidence at 5.8% and vitreous floaters at 5.2%, demonstrating good safety and tolerability, which bolsters confidence for future commercialization efforts.
See More
EyePoint Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: EyePoint Pharmaceuticals reported a Q4 GAAP EPS of -$0.81, missing expectations by $0.08, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company generated $0.62 million in revenue for Q4, a staggering 94.7% year-over-year drop, falling short of market expectations by $0.39 million, reflecting weak product sales that could negatively impact future cash flows.
- Funding Outlook: EyePoint anticipates that its cash and cash equivalents as of December 31, 2025, will enable operations through Q4 2027, suggesting a stable funding position for key milestones in its Phase 3 wet AMD and DME programs.
- Clinical Trial Progress: The company plans to advance its Phase 3 clinical trial for wet AMD in 2026 and fully fund the pivotal DME program, demonstrating strategic positioning in the treatment landscape and confidence in future market opportunities.
See More
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4
- Earnings Announcement Date: EyePoint Pharmaceuticals is set to release its Q4 earnings report on March 4 before the market opens, drawing significant attention amid ongoing performance challenges.
- Declining Earnings Expectations: The consensus EPS estimate stands at -$0.75, reflecting a 17.2% year-over-year decline, indicating persistent challenges in profitability that may impact investor confidence.
- Significant Revenue Decline: The consensus revenue estimate is $1.01 million, down 91.3% year-over-year, highlighting major difficulties in market competition and product sales, which could lead to stock price volatility.
- Estimate Revision Activity: Over the past three months, EPS estimates have seen one upward revision and one downward revision, suggesting mixed analyst sentiment regarding the company's future performance and increasing market uncertainty.
See More
iShares Expanded Tech-Software ETF Underperforms
- ETF Performance Decline: The iShares Expanded Tech-Software Sector ETF fell approximately 4.9% in Monday afternoon trading, indicating a weak sentiment in the tech software sector that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Within the ETF, Tenable Holdings saw a significant drop of about 10.1%, while Ringcentral declined by approximately 9.8%, reflecting challenges faced by these companies that may negatively impact the overall ETF performance.
- Market Reaction: As tech stocks face pressure, investors may reassess their investment strategies in the tech software industry, potentially leading to decreased liquidity for the ETF and affecting its future market performance.
- Investor Attention: With increasing market volatility, investors should closely monitor the performance of the ETF's component stocks to timely adjust their portfolios and mitigate potential losses.
See More
EYPT Options Trading Analysis and Strategies
- Put Option Appeal: The current bid for the $12.50 put option is $2.50, and if an investor sells this option, they commit to buying the stock at $12.50, effectively lowering their cost basis to $10.00, which is about a 4% discount from the current price of $13.03, making it attractive for those interested in EYPT shares.
- Return Potential Analysis: Should the put option expire worthless, the investor would realize a 20% return on their cash commitment, equating to an annualized yield of 36.69%, highlighting the potential attractiveness of this strategy in the current market environment.
- Call Option Returns: The $15.00 call option has a bid of $3.00, and if an investor buys EYPT shares at $13.03 and sells this call option, they could achieve a total return of 38.14% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Volatility Comparison: The implied volatility for the put option is 149%, while for the call option it is 147%, compared to a trailing twelve-month actual volatility of 73%, indicating a high market expectation for future volatility in EYPT shares, which necessitates careful risk assessment by investors.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific company names and rating changes are not detailed in the report, such adjustments typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention.
- Market Reaction Expectations: The adjustments made by analysts may trigger market volatility, especially when investor sentiment towards certain stocks is sensitive, potentially leading to increased trading volumes in the short term.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their strategies regarding buying or holding these stocks, thereby affecting overall market liquidity.
See More
EyePoint, Inc. Q4 2025 Earnings Call Insights
- Significant Clinical Progress: EyePoint initiated pivotal Phase III trials for DME in Q4 2025, marking a crucial advancement for DURAVYU, with top line data for wet AMD expected in mid-2026, thereby laying a strong foundation for future market potential.
- Strong Financial Position: By the end of 2025, EyePoint reported $306 million in cash and investments, despite a significant drop in Q4 net revenue to $0.6 million from $11.6 million in Q4 2024, primarily due to the recognition of deferred revenue from the YUTIQ licensing agreement.
- Rising Operating Expenses: Operating expenses for Q4 2025 reached $71 million, up from $57 million in the prior year, reflecting increased trial activities for DURAVYU, although the company expects its cash runway to extend into Q4 2027.
- Positive Safety Data: Among 191 patients, DURAVYU exhibited a low adverse event rate, with cataract incidence at 5.8% and vitreous floaters at 5.2%, demonstrating good safety and tolerability, which bolsters confidence for future commercialization efforts.
See More
EyePoint Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: EyePoint Pharmaceuticals reported a Q4 GAAP EPS of -$0.81, missing expectations by $0.08, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company generated $0.62 million in revenue for Q4, a staggering 94.7% year-over-year drop, falling short of market expectations by $0.39 million, reflecting weak product sales that could negatively impact future cash flows.
- Funding Outlook: EyePoint anticipates that its cash and cash equivalents as of December 31, 2025, will enable operations through Q4 2027, suggesting a stable funding position for key milestones in its Phase 3 wet AMD and DME programs.
- Clinical Trial Progress: The company plans to advance its Phase 3 clinical trial for wet AMD in 2026 and fully fund the pivotal DME program, demonstrating strategic positioning in the treatment landscape and confidence in future market opportunities.
See More
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4
- Earnings Announcement Date: EyePoint Pharmaceuticals is set to release its Q4 earnings report on March 4 before the market opens, drawing significant attention amid ongoing performance challenges.
- Declining Earnings Expectations: The consensus EPS estimate stands at -$0.75, reflecting a 17.2% year-over-year decline, indicating persistent challenges in profitability that may impact investor confidence.
- Significant Revenue Decline: The consensus revenue estimate is $1.01 million, down 91.3% year-over-year, highlighting major difficulties in market competition and product sales, which could lead to stock price volatility.
- Estimate Revision Activity: Over the past three months, EPS estimates have seen one upward revision and one downward revision, suggesting mixed analyst sentiment regarding the company's future performance and increasing market uncertainty.
See More
iShares Expanded Tech-Software ETF Underperforms
- ETF Performance Decline: The iShares Expanded Tech-Software Sector ETF fell approximately 4.9% in Monday afternoon trading, indicating a weak sentiment in the tech software sector that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Within the ETF, Tenable Holdings saw a significant drop of about 10.1%, while Ringcentral declined by approximately 9.8%, reflecting challenges faced by these companies that may negatively impact the overall ETF performance.
- Market Reaction: As tech stocks face pressure, investors may reassess their investment strategies in the tech software industry, potentially leading to decreased liquidity for the ETF and affecting its future market performance.
- Investor Attention: With increasing market volatility, investors should closely monitor the performance of the ETF's component stocks to timely adjust their portfolios and mitigate potential losses.
See More
EYPT Options Trading Analysis and Strategies
- Put Option Appeal: The current bid for the $12.50 put option is $2.50, and if an investor sells this option, they commit to buying the stock at $12.50, effectively lowering their cost basis to $10.00, which is about a 4% discount from the current price of $13.03, making it attractive for those interested in EYPT shares.
- Return Potential Analysis: Should the put option expire worthless, the investor would realize a 20% return on their cash commitment, equating to an annualized yield of 36.69%, highlighting the potential attractiveness of this strategy in the current market environment.
- Call Option Returns: The $15.00 call option has a bid of $3.00, and if an investor buys EYPT shares at $13.03 and sells this call option, they could achieve a total return of 38.14% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Volatility Comparison: The implied volatility for the put option is 149%, while for the call option it is 147%, compared to a trailing twelve-month actual volatility of 73%, indicating a high market expectation for future volatility in EYPT shares, which necessitates careful risk assessment by investors.
See More
